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Abstract
Background: Extent of myocardial fibrosis (MF) determined using late gadolinium enhanced (LGE) predicts outcomes,
but gadolinium is contraindicated in advanced renal disease. We assessed the ability of native T1-mapping to identify
and quantify MF in aortic stenosis patients (AS) as a model for use in haemodialysis patients.
Methods: We compared the ability to identify areas of replacement-MF using native T1-mapping to LGE in 25 AS
patients at 3 T. We assessed agreement between extent of MF defined by LGE full-width-half-maximum (FWHM) and
the LGE 3-standard-deviations (3SD) in AS patients and nine T1 thresholding-techniques, with thresholds set 2-to-9
standard-deviations above normal-range (1083 ± 33 ms). A further technique was tested that set an individual
T1-threshold for each patient (T11SD). The technique that agreed most strongly with FWHM or 3SD in AS patients
was used to compare extent of MF between AS (n = 25) and haemodialysis patients (n = 25).
Results: Twenty-six areas of enhancement were identified on LGE images, with 25 corresponding areas of discretely
increased native T1 signal identified on T1 maps. Global T1 was higher in haemodialysis than AS patients (1279 ms ± 5.
8 vs 1143 ms ± 12.49, P < 0.01). No signal-threshold technique derived from standard-deviations above normal-range
associated with FWHM or 3SD. T11SD correlated with FWHM in AS patients (r = 0.55) with moderate agreement
(ICC = 0.64), (but not with 3SD). Extent of MF defined by T11SD was higher in haemodialysis vs AS patients (21.92% ± 1
vs 18.24% ± 1.4, P = 0.038), as was T1 in regions-of-interest defined as scar (1390 ± 8.7 vs 1276 ms ± 20.5, P < 0.01). There
was no difference in the relative difference between remote myocardium and regions defined as scar, between groups
(111.4 ms ± 7.6 vs 133.2 ms ± 17.5, P = 0.26).
Conclusions: Areas of MF are identifiable on native T1 maps, but absolute thresholds to define extent of MF could not
be determined. Histological studies are needed to assess the ability of native-T1 signal-thresholding techniques to
define extent of MF in haemodialysis patients.
Data is taken from the PRIMID-AS (NCT01658345) and CYCLE-HD studies (ISRCTN11299707).
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Background
The development of myocardial fibrosis (MF) is common
to many cardiac pathologies and is associated with poor
outcomes [1, 2]. The pathogenesis of MF differs across
disease states, but in diseases of pressure or volume over-
load, patients initially develop diffuse interstitial myocar-
dial fibrosis (DMF) [3]. Over time, increasing levels of
DMF lead to decreased capillary density and myocardial
ischaemia, with subsequent myocyte apoptosis and devel-
opment of replacement fibrosis (scar) [4]. Extent of MF is
strongly related to adverse outcomes in a number of con-
ditions [5, 6]. Patients with chronic kidney disease (CKD)
and end stage renal disease (ESRD) are known to have
high levels of MF that are unrelated to coronary artery
disease that starts as DMF and progresses with stage of
CKD, being most severe in patients on dialysis [7].
Percentage area of LV fibrosis has been shown to be a
stronger predictor of cardiovascular outcomes than
extent of myocyte hypertrophy in haemodialysis pa-
tients and an independent predictor of mortality [8].
The ability to non-invasively detect and define extent
of MF in patients with advanced renal disease has
significant implications [9, 10].
The assessment of MF with late gadolinium enhanced
(LGE) cardiac magnetic resonance imaging (CMR) is
well established and validated against histology in
experimental models [11–13]. LGE accurately defines
areas of replacement fibrosis due to the increased extra-
cellular volume and prolonged washout of contrast
related to decreased capillary density within fibrotic
myocardial tissue [14, 15]. The presence and extent of
scarring defined by LGE is strongly related to adverse
outcomes in a number of conditions, independent of
cardiac volumes and ejection fraction [1, 5, 6]. Quantify-
ing extent of MF is possible using LGE signal intensity
(SI) thresholding techniques such as full-width-half max-
imum (FWHM) [16], or the 3-standard deviation (3SD)
technique which has recently been shown to correlate
with extent of MF in aortic stenosis (AS) patients [17].
The reproducibility of these techniques are excellent,
but tend to underestimate total fibrosis burden [18, 19],
due to the dependence of the technique in demonstrat-
ing a difference between signal intensity of normal and
fibrotic myocardial tissue [20]. Administration of gado-
linium based contrast agents are not possible in patients
with advanced renal disease and those on dialysis due to
the risk of nephrogenic systemic fibrosis [21], precluding
qualitative or quantitative assessment of MF.
The potential for native T1 mapping to quantify DMF
has been shown in a wide range of diseases [22–27],
including patients with CKD and patients on haemodi-
alysis [28–30]. The generation of native T1 parametric
maps allows not only qualitative assessment of myocar-
dium on colour coded parametric maps, but pixel-wise
quantification of T1 values [30, 31]. The technique cor-
relates well with levels of MF on histology in AS patients
[22] and defining abnormal areas of myocardium is not
solely reliant on demonstrating a difference in SI to an
area of normal myocardium as in LGE [32]. Whether
combined visual and quantitative threshold analysis of
parametric native T1 maps can reliably identify and
quantify extent of MF is not known. Aortic stenosis is a
disease of pressure overload, which shares several mor-
phological myocardial characteristics with uraemic car-
diomyopathy, including development of left ventricular
hypertrophy, DMF and replacement fibrosis. Comparing
LGE images to native T1 images in AS patients serves as
a useful model to explore the possibility of using native
T1 mapping to identify replacement MF and extent of
MF in patients unable to receive gadolinium based
contrast agents.
We hypothesised that it is possible to visually identify
and quantify areas of replacement fibrosis in ESRD using
native T1 mapping.
Methods
Patients with AS were recruited from the PRIMID-AS
study (NCT01658345) and haemodialysis patients were
recruited from the CYCLE-HD study (ISRCTN11299707).
The design and rationale for both studies are as
previously described [33, 34]. Both studies received
ethical approval from the National Research Ethics
Service Committee East Midlands (REC references
11/EM/0410 and 14/EM/1190, respectively). All
participants gave written and informed consent. The
scans of 126 patients from the PRIMID-AS study
(from host centre, Leicester, UK) and the scans of the
first 44 patients to enter the CYCLE-HD study were
assessed included.
Image acquisition
Patients from the PRIMID-AS and the CYCLE-HD
studies were scanned on the same 3 T MRI platform
(Skyra, Siemens Medical Imaging, Erlangen, Germany)
using an 18-channel phased-array anterior coil. CMR
protocols for acquisition of LGE images (AS only) and
native T1 maps are as previously described [30, 35].
Briefly, pre-contrast short-axis native T1 maps were ac-
quired at the mid-ventricular level using the modified
look-locker inversion recovery (MOLLI) sequence. Im-
ages were acquired using free-breathing with motion
correction (MOCO), ECG-gated single-shot MOLLI
sequence [36] with 3(3)3(3)5 sampling pattern and the
following typical parameters for both studies: slice thick-
ness 8.0 mm, field of view 300 × 400 mm, flip angle 50
degrees (PRIMID-AS cohort) and 35 (CYCLE-HD
cohort), minimum TI 120 ms, inversion-time increment
80 ms. Patients from the PRIMID-AS study underwent a
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comprehensive adenosine stress and rest perfusion study
that included left-ventricular (LV) LGE imaging 7–10 min
after administration of gadolinium gadopentate (Gadovist,
Bayer, Faversham, United Kingdom) 0.15 mmol/kg.
Visual comparison of LGE images and native T1 maps
Native T1 maps and LGE images were assessed separately,
offline, two-weeks apart by blinded observers. For patients
with AS, mid-ventricular LGE images were assessed by
two, blinded observers (AS, GPM) for the presence of late
gadolinium enhancement. Strongly enhancing areas were
scored ‘2’, and weakly enhancing areas were scored ‘1’
(Fig. 1). Corresponding mid-ventricular native T1 maps of
AS patients were assessed (separately) for areas of
discretely increased signal likely to represent scar fi-
brosis (MGB, GPM). The locations of areas defined as
scarring by the two techniques were compared. For
haemodialysis patients, two blinded observers (MGB,
GPM) assessed the mid-ventricular native T1 maps
for areas of discretely increased signal likely to repre-
sent myocardial scar.
Image quality was assessed as being excellent, good,
acceptable or poor.
Quantitative image analysis
All scans were analysed offline by a single, blinded
observer (MGB).
Native T1 mapping
Mid-ventricular native T1 parametric maps derived from
MOCO MOLLI images were used for native T1 analysis
due to superior intra- and inter-observer variability
compared to analysing the individual image series [37].
Circumferential native T1 values of mid-ventricular
slices were analysed as previously described using the
native T1 analysis module of the software package
CMR42 (Circle, Cardiovascular Imaging, Calgary, Alberta,
Canada) [30].
Native T1 thresholds to assess extent of MF in
patients with AS Native T1 thresholds were systematic-
ally tested by deriving absolute values 2 to 9 standard
deviations above the normal range for the 3 T CMR
scanner (1083 ± 33 ms) [30]. This gave absolute thresh-
olds of 1149 ms, 1182 ms, 1215 ms, 1248 ms, 1282 ms,
1314 ms, 1347 ms and 1380 ms.
One further technique was tested which set an individ-
ual native T1 threshold for each patient. This individual
Fig. 1 a Mid-ventricular LGE image of an AS patient with LGE scored 1 (diffuse subtle enhancement). Enhancement seen at RV inferior insertion
point and septal mid-wall (arrows). b Mid-ventricular LGE image of AS patient scored 2 (strong and discrete enhancement). Discrete enhancement
seen at RV inferior insertion point (arrow). c Mid-ventricular native T1 map of the same patient shown in Fig. ‘1a’. Areas of discretely increased signal
visible in the same distribution as enhancing areas on LGE image (arrows) d Mid-ventricular native T1 map of the same patient shown in Fig. ‘1b’.
Discrete area of increased native T1 signal clearly visible at RV insertion point (arrow)
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threshold was set by adding the standard deviation (SD)
of the mean T1 in the region of interest thought to
represent scar to the mean circumferential native T1 for
the patient (T11SD).
The following techniques were used to derive native
T1 values for the above calculations:
1. Native T1 parametric maps were inspected in Argus
Viewer (Siemens Healthcare, Erlangen, Germany).
On T1 maps where an area of discretely increased
signal intensity could be seen, a region of interest
was drawn around the area of highest signal and
the mean and standard deviation of the T1 for that
region was recorded (Fig. 2a).
2. Native T1 maps were then loaded into the
LGE-tissue characterization module of the software
package CMR42 (Circle, Cardiovascular Imaging,
Calgary, Alberta, Canada). Epicardial and
endocardial contours were drawn to define the
myocardium. The absolute T1 signal threshold
being tested (as above) was applied manually to give
the percentage of myocardium within that signal
intensity. Thresholds for the T11SD technique were
derived and applied individually for each patient
(Fig. 2b).
Late gadolinium enhanced images
Corresponding, mid-ventricular LGE images were
analysed using software package CMR42. Epicardial and
endocardial contours were applied and analysed using
FWHM and the 3SD technique to generate a percentage
area of fibrosis burden as previously described [17, 38].
The Full width half-maximum technique defines the en-
hanced area by using 50% of the maximum signal found
within the enhanced area (Fig. 1c). The 3SD technique
defines enhanced areas as 3 standard deviations above
remote (normal) myocardium.
Statistical analysis
Statistical analysis was undertaken using SPSS-22
software (Statistical Package for the Social Sciences,
Chicago, IL, USA) and Graphpad Prism version 6.04
Fig. 2 a: Native T1 map of a haemodialysis patient. Region of interested (white) defining visual area of greatest signal increase at right ventricular
inferior insertion point. Black arrow shows septal mid-wall discretely increased native T1 signal b: The same Native T1 in CMR42 tissue
characterization module set T1 threshold defined by the global native T1 for the patient plus the standard deviation of the region of interest
circled as the area of highest signal increase (defined in Argus in 1A) (T11SD technique). c: Mid-ventricular late gadolinium enhanced image of an
aortic stenosis patient analysed using full-width half-maximum in the CMR-42 tissue characterization module. d: Corresponding native T1 map of
the same patient with aortic stenosis analysed with T11SD technique
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(GraphPad Software, Inc., La Jolla, CA, USA). Normality
was assessed using the Shapiro–Wilk test, histograms,
and Q–Q plots. Parametric data are expressed as mean
± standard deviation and non-parametric data are
expressed as median (interquartile range). Chi-squared
tests and Fishers exact tests were used to assess for differ-
ences between categorical variables and are expressed as
‘count’ (%). Continuous variables were compared by paired
or independent t-tests and Mann-Whitney U tests.
Agreement between the native T1 signal thresholding
techniques and LGE analysis with FWHM to assess
extent of fibrosis was assessed with intra-class correl-
ation coefficient (ICC) and Bland-Altman analysis.
Correlations between variables were assessed using
Pearson’s and Spearman’s-rank analysis for normally
and non-normally distributed data respectively.
Inter-observer and intra-observer variability were
assessed using ICC and Bland-Altman analysis. Re-
peatability was considered ‘excellent’ for ICC > 0.9,
‘good’ for ICC between 0.8–0.89, moderate for ICC
between 0.5–0.79 and poor for < 0.5. A two-tailed
p-value < 0.05 was considered statistically significant.
Assessment of extent of MF in haemodialysis patients
Any native T1 thresholding technique that showed a
significant correlation with FWHM or 3SD in AS pa-
tients was used to assess extent of MF in haemodialysis
patients. Inter and intra-observer variability of native T1
mapping thresholding techniques were conducted on
the native T1 maps of 10 haemodialysis patients.
Inter-observer variability was assessed by comparing the
results of two blinded observers and intra-observer
variability was assessed by comparing the results of 1
blinded observer who undertook re-analysis of 10 scans
at random 4 weeks after initial analysis.
Results
Participant characteristics
Demographic, clinical, biochemical and additional CMR
data are shown in Table 1. There were no differences in
gender or BMI between the study groups. The AS pa-
tients were older than haemodialysis patients. There
were no significant associations between age and native
T1 in haemodialysis or AS patients (r = 0.22 and r = 0.21
respectively). Systolic blood pressure was significantly
lower in haemodialysis patients without areas of
discretely increased signal on native T1 maps compared
to AS patients and to haemodialysis patients with areas
of discretely increased signal on native T1 maps.
Visual assessment and image quality on native T1 maps
and LGE images
Twenty-five out of 126 AS patients had areas of
enhancement in a mid-ventricular LGE image (Fig. 3).
All of these patients had a corresponding native T1 map
at the same slice position that were assessed separately
for areas of discretely increased signal. Fifteen of the
LGE images were scored ‘excellent’, 8 were scored ‘good’
and 2 were scored as acceptable. Similarly, 14 of the
native T1 maps were scored as ‘excellent’ and 11 were
scored as ‘good’. In patients with AS, 12 areas of
enhancement on LGE images were scored as ‘1’ and 13
were scored as ‘2’. Twenty six areas of enhancement
were identified on LGE images, with 25 corresponding
areas of discretely increased native T1 signal identified
on corresponding mid-ventricular native T1 maps
(Table 2).
The mid-ventricular native T1 maps of 44 haemodialy-
sis patients were reviewed and areas of discretely
enhanced signal were identified in 25 patients (Fig. 3).
For haemodialysis patients, 24 of the native T1 maps
were scored as ‘excellent’ and 20 were scored as ‘good’.
Locations of areas of discretely increased signal are
shown in Table 2.
Global and regional native T1 in AS and haemodialysis
patients
Global native T1 values and native T1 values within
discrete regions of interest thought to represent MF for
AS and haemodialysis patients are shown in Table 3.
Circumferential native T1 values were significantly lower
in AS patients (n = 25), compared to patients on haemo-
dialysis patients (n = 44) (1143 ms ± 12.49 vs 1268.2 ±
32.5, P < 0.001) (Fig. 4). Patients on haemodialysis who
had areas of discretely increased signal on T1 mapping
(n = 25) had significantly higher circumferential native
T1 than those without (n = 19) (1279 ms ± 5.8 vs
1254 ms ± 7.4, P = 0.01).
For AS patients, regions of interest on native T1 that
corresponded to an area of LGE scored as a ‘1’ (n = 12)
were significantly lower than regions of interest on
native T1 that corresponded to an area of LGE that was
scored as a ‘2’ (n = 13) (1213 ms ± 10.2 vs 1334 ms ±
30.7, P < 0.01) (Fig. 5). The areas of discretely enhanced
native T1 signal, defined by regions of interest, were
significantly higher in haemodialysis patients (n = 25)
than in patients with AS (n = 25) (1390 ± 8.7 vs
1276 ms ± 20.5, P < 0.01) and significantly higher than
the regions of interest that corresponded with LGE scored
‘2’ (n = 13) (1390 ± 8.7 vs 1334 ± 30.72, P = 0.03) (Fig. 3).
The difference in native T1 signal in the region of
increased signal intensity and that of remote myocardium
was not significantly different between haemodialysis pa-
tients and patients with AS (111.4 ms ± 7.6 vs
133.2 ms ± 17.5, P = 0.26) (Fig. 4).
Nine patients on haemodialysis had a previous
history of coronary artery disease and 16 patients
did not. There were no differences in the global
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native T1 times or the T1 times with regions of
greater signal intensity for patients with a prior
history of coronary artery disease and those without
(global native T1 1279.2 ± 30.6 vs 1278.7 ± 28.9, p = 0.37
and highest regional native T1 1366.0 ± 36.5 vs 1404.0 ±
41.6, p = 0.35).
Native T1 thresholding techniques compared to FWHM in
AS patients
Absolute native signal thresholds
None of the absolute signal thresholding techniques
used to define extent of MF based on an absolute value
derived from standard deviations above our normal
Table 1 Demographic details of Aortic Stenosis and haemodialysis patients
Variable Aortic Stenosis patients (areas of
discrete signal increase on native T1)
(n = 25)
Haemodialysis patients areas of
discrete signal increase on native T1)
(n = 25)
Haemodialysis patients (no areas of
discrete signal increase on native T1)
(n = 19)
Age (years) 66.9 ± 13.7 58.1 ± 16.5 49.9 ± 16.9
Male (n, %) 18 (72) 18 (72) 16 (84)
BMI (kg/m2) 29.4 ± 4.4 27.8 ± 6.8 27.9 ± 6.4
Dialysis Vintage (months) – 35.4 ± 25.8 26.9 ± 21.6
Haemoglobin (g/L) 14.5 ± 1.2 11.4 ± 1.6 10.4 ± 1.6
HbA1c (%) 5.9 ± 0.9 5.4 ± 1.8 5.4 ± 0.6
SBP (mmHg) 158.8 ± 21.4 152.6 ± 22.5 127.6 ± 25.8
DBP (mmHg) 78.3 ± 9.6 79.5 ± 10.5 72.5 ± 19.1
HR (bpm) 70.1 ± 10 72.8 ± 12.5 78.1 ± 11.1
Past medical and drug history
Hypertension (n, %) 18 (72) 21 (84) 11 (58)
Diabetes (n, %) 4 (16) 7 (28) 4 (21)
CAD (n, %) 11 (44) 9 (36) 4 (21)
Prev MI (n, %) 3 (12) 5 (20) 1 (5)
ACEi (n, %) 7 (28) 2 (8) 1 (5)
ARB (n, %) 4 (16) 3 (12) 1 (5)
Diuretic (n, %) 7 (28) 3 (12) 4 (21)
Beta Blocker (n, %) 10 (40) 12 (48) 6 (32)
Statin (n, %) 17 (68) 14 (56) 5 (26)
Calcium Channel Blocker (n, %) 11 (44) 11 (44) 5 (26)
Number of antihypertensives 1.6 ± 1.2 1.4 ± 0.9 1.3 ± 1.1
Left Ventricular mass and volumes (CMR)
LVEDV (ml) 190.3 ± 43.4 198.8 ± 54.3 160.1 ± 48
LVEF (%) 56.5 ± 6.5 52.2 ± 6.4 50.5 ± 6.2
LVM (g) 135.4 ± 42.4 116.1 ± 29.4 104.1 ± 45.3
LVM/LVEDV (g/ml) 0.71 ± 0.1 0.59 ± 0.1 0.62 ± 0.1
Mean values with standard deviation expressed as n ± SD. N, % = Chi-squared. bpm, beats per minute; ACEi angiotensin converting enzyme inhibitor, ARB
angiotensin receptor blocker, CAD coronary artery disease, CMR cardiac MRI, DBP diastolic blood pressure, HR heart rate, HTN hypertension, LVEDV left ventricular
end-diastolic volume, LVEF left ventricular ejection fraction, LVMi left ventricular mass index, MI myocardial infarction, SBP systolic blood pressure
Fig. 3 Flow diagram of patients included in study and numbers of patients with areas of discretely increased signal on native T1 maps
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range for native T1 showed significant correlation or
agreement with extent of MF defined by either FWHM
or 3SD (Table 4).
T11SD
The native T1 threshold derived using T11SD was
derived individually for each patient and was different in
each case. There was no correlation or agreement
between mean percentage area defined as MF by T11SD
and 3SD. The mean percentage area defined as ‘MF’ by
T11SD was higher than the mean area identified as scar
using FWHM (18.24% ± 1.4 vs 14.38 ± 1.5, P = 0.043)
(Fig. 4), but there was a moderate correlation and agree-
ment between the two techniques (r = 0.55, P < 0.01,
ICC = 0.64, P < 0.01). Bland-Altman analysis suggested
the T11SD systematically overestimated extent of scar
burden by 4.3% compared to FWHM (Bias 4.3 (SD of
bias 6.8), limits of agreement − 9.1 - 17.7).
Extent of myocardial fibrosis defined by T11SD in AS
patients and HD patients
Mean percentage identified as ‘MF’ using T11SD was
significantly greater in haemodialysis patients (n = 25)
than patients with AS (n = 25) (21.92% ± 1 vs 18.24% ±
1.4, P = 0.038) (Fig. 6).
Inter and intra-observer variability of T11SD in HD patients
Inter- and intra-observer variability for 10 haemodialysis
patients are shown in Table 5. Bland-Altman analysis re-
vealed no evidence of systematic bias, and all data points
were within 95% confidence intervals (data not shown).
Discussion
Although we have shown that areas of discretely increased
signal on native T1 mapping are visible and appear to cor-
respond to areas LGE, we were not able to define an abso-
lute native T1 signal threshold to define the extent of MF
compared to FWHM or 3SD in AS patients. The areas of
myocardium identified as having discretely increased sig-
nal on native T1 mapping in patients with AS were mostly
located at the right ventricular inferior insertion point and
matched well to enhanced areas on LGE images. The right
ventricular insertion point was also a common area to
show discretely increased native T1 signal in haemodialy-
sis patients. Additionally in haemodialysis patients there
were a large number of areas of discretely increased native
T1 signal in the septum in a mid-wall pattern similar to
that described by Mark et al. in the largest study using
LGE in haemodialysis patients, before the risks of nephro-
genic systemic fibrosis became apparent [39].
The reasons for not being able to define an absolute
native T1 threshold to define extent of MF are not clear.
Commentators have suggested that it should be possible
to define absolute thresholds for identification of MF
using T1 mapping, but acknowledge that there will be
significant overlap in values between diseases [40]. Our
observation that quantitative native T1 analysis differen-
tiated between LGE scored ‘1’ and LGE scored ‘2’ in AS
patients supports the idea that the technique is able to dif-
ferentiate between levels of disease on a spectrum from
DMF to replacement MF for discrete disease populations.
Indeed studies have shown that native T1 threshold-based
analysis for characterization of replacement MF in chronic
myocardial infarction are excellent [41]. An alternative
Table 2 Location of signal enhancement on LGE images in AS patients and of discretely increased signal on native T1 maps in AS
and haemodialysis patients
Area of enhancement/increased signal intensity LGE images in AS
patients (number)
Native T1 maps in AS
patients (number)
Native T1 map in HD
patients (number)
Inferior insertion point 17 17 17
Anterior insertion point 3 3 3
Septal mid-wall 1 1 14
Infero-lateral mid-wall 3 2 1
Lateral mid-wall 2 2 0
Inferior wall 0 0 4
HD haemodialysis, AS aortic stenosis
Table 3 Global and regional native T1 values in patients with aortic stenosis and those on haemodialysis
Patient Group Circumferential
Native T1 (ms)
Native T1 in region of interest
thought to represent scar (ms)
Patients with aortic stenosis (n = 126) 1125.8 ± 57.5 –
Patients with aortic stenosis with areas of discretely increased signal on native T1 (n = 25) 1142.6 ± 62.4 1275.8 ± 102.4
Patients on haemodialysis (n = 44) 1268.2 ± 32.5 –
Patients on haemodialysis with areas of discretely increased signal on native T1 (n = 25) 1278.9 ± 28.9 1390.3 ± 43.3
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explanation for not being able to establish an absolute
value to define the total extent of MF may be due to add-
itional influences on myocardial native T1 beyond levels
of MF. The observation that differences between native
T1 in areas of discretely increased signal and remote myo-
cardium in haemodialysis and AS patients were similar
(111.4 ± 7.6 ms and 133.2 ± 17.5 ms) despite significantly
higher native T1 values in haemodialysis patients suggests
that global differences in background myocardium may
account for the absolute differences in native T1 values in
areas of discretely increased signal. These differences in
background myocardium may be related to many factors,
including levels of inflammation, oedema or amyloid infil-
tration (known to lengthen T1), or iron or triglyceride de-
position (known to shorten T1) as well as absolute levels
of MF. Indeed, factors unrelated to myocardial tissue such
as haemoglobin concentration/haematocrit, blood vessels
or capillary density may also introduce systematic differ-
ences between disease populations [17]. Theoretically the
T11SD technique we have described accounts for differ-
ences in background myocardium on an individual basis.
However, the technique is still reliant on visually identify-
ing an area of discrete signal increase thought to be re-
placement MF (and is consequently subject to the same
limitations of underestimating extent of MF as LGE SI
techniques), but thereafter the individual threshold is set
using the patient’s own native T1 values. For patients with
high levels of myocardial inflammation or potentially at
risk of myocardial oedema (such as haemodialysis pa-
tients), these influences on T1 are accounted for in the
Fig. 4 Circumferential native T1 in haemodialysis patients with areas of visually increased signal, haemodialysis patients without areas of visually
increased signal and aortic stenosis patients with areas of visually increased signal
Fig. 5 a: Comparison of corresponding areas of discretely increased signal on native T1 in aortic stenosis patients with LGE images scored ‘1’ and
scored ‘2’. b: Native T1 signal within region of discrete signal increase in haemodialysis patients compared to native T1 signal within region of
discrete signal increase in aortic stenosis patients. c: Difference in native T1 between remote myocardium and myocardium within areas of
discretely increased signal between haemodialysis and aortic stenosis patients. ms, milliseconds; HD, haemodialysis,; AS, aortic stenosis; LGE, late
gadolinium enhancement
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calculation of extent of MF. The fact that we were able
to demonstrate moderate agreement between extent of
MF defined by FWHM and T11SD supports this the-
ory, although as the technique did not correlated with
3SD confirmatory studies, validation against histology
and refining of the technique are required. This finding
may have implications that extend beyond use in
haemodialysis patients, as non-enhanced scans should
now be considered (when suitable) for patients with
gadolinium brain deposits.
Table 4 Agreement between native T1 thresholding techniques and FWHM to define extent of myocardial fibrosis
Native T1 threshold/technique
(standard deviation above
normal for native T1)
Extent of fibrosis
defined by FWHM (%)
Extent of fibrosis defined
by technique (%)
Correlation between FWHM
and T1 technique (r)
Agreement between extent of
MF defined by T1 thresholding
technique and FWHM (ICC)
1149 ms (2SD) 14.38 ± 1.5 44.6 ± 33.7* 0.07 0.06
1182 ms (3SD) 14.38 ± 1.5 32.8 ± 32.6* 0.1 0.07
1215 ms (4SD) 14.38 ± 1.5 22.9 ± 26.3 0.11 0.11
1248 ms (5SD) 14.38 ± 1.5 13.3 ± 17.3 0.15 0.2
1281 ms (6SD) 14.38 ± 1.5 6.7 ± 10* 0.21 0.26
1314 ms (7SD) 14.38 ± 1.5 3.5 ± 5* 0.23 0.16
1357 ms (8SD) 14.38 ± 1.5 1.8 ± 2.3* 0.17 0.05
1380 ms (9SD) 14.38 ± 1.5 1 ± 1.3* 0.02 0.03
T11SD 14.38 ± 1.5 18.24% ± 1.4* 0.55† 0.64††
Native T1 threshold/technique
(standard deviation above
normal for native T1)
Extent of fibrosis
defined by LGE
3SD (%)
Extent of fibrosis defined
by technique (%)
Correlation between LGE
3SD and T1 technique (r)
Agreement between extent of
MF defined by T1 thresholding
technique and LGE 3SD (ICC)
1149 ms (2SD) 21.1 ± 12.1 44.6 ± 33.7* 0.03 0.04
1182 ms (3SD) 21.1 ± 12.1 32.8 ± 32.6* 0.075 0.1
1215 ms (4SD) 21.1 ± 12.1 22.9 ± 26.3 0.11 0.18
1248 ms (5SD) 21.1 ± 12.1 13.3 ± 17.3 0.09 0.18
1281 ms (6SD) 21.1 ± 12.1 6.7 ± 10* 0.08 0.16
1314 ms (7SD) 21.1 ± 12.1 3.5 ± 5* 0.11 0.17
1357 ms (8SD) 21.1 ± 12.1 1.8 ± 2.3* 0.19 0.15
1380 ms (9SD) 21.1 ± 12.1 1 ± 1.3* 0.26 0.12
T11SD 21.1 ± 12.1 18.24% ± 1.4 0.1 0.2
Abbreviations: FWHM Full width half maximum, ICC intra-class correlation coefficient, ms milliseconds, SD Standard deviation. *denotes significant difference
between native T1 threshold technique for extent of fibrosis and extent of fibrosis defined by FWHM (P < 0.05). †denotes significant correlation between FWHM
and native T1 thresholding technique (P < 0.05). ††denotes significant agreement between FWHM and native T1 thresholding technique (P < 0.05)
Fig. 6 a: Percentage area defined as scar by T11SD on native T1 mapping compared to percentage area defined as scar by FWHM on LGE
images in AS patients. b: Comparison of extent of scar defined by T11SD between aortic stenosis patients and patients on haemodialysis. AS,
aortic stenosis; HD, haemodialysis
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The absolute differences between native T1 in areas of
discretely increased signal and remote myocardium
between haemodialysis and AS patients (111.4 ms and
133.2 ms) represent a 9.6 and 10.4% increase in native
T1 signal above background myocardium. These thresh-
olds are lower than the 21% difference described in a
study that examined the use of native T1 mapping at
defining scarring following myocardial infarction at 3 T
[41]. This is unsurprising for two reasons. Firstly, the
density of fibrosis following myocardial infarction is
likely to be greater, and often transmural, causing rela-
tively higher native T1 times. Secondly, the background
(remote) myocardium in patients following acute myo-
cardial infarction is likely to have less DMF than
expected in patients with both AS and those on haemo-
dialysis. Consequently, remote myocardial native T1 is
likely to be significantly lower in patients following acute
myocardial infarction, and the difference between re-
mote myocardium and scarred myocardium greater.
The inter- and intra-observer variability for T11SD in
haemodialysis patients were excellent, and equivalent to
assessment with FWHM [19]. This is essential as it is
the repeatability of LGE SI techniques, rather than their
absolute accuracy, that have made them useful bio-
markers of extent of MF in multi-centre clinical trial
work. The T11SD technique is experimental, however,
and theoretically is subject to the same limitations as
LGE for identifying DMF and therefore should be used
as hypothesis generating only.
Circumferential native T1 values were significantly
higher in haemodialysis patients than AS patients. This
difference in myocardial characteristics may be due to
higher levels of DMF; indeed histological studies support
this hypothesis as non-ischaemic DMF is a prominent
feature of cardiomyopathy in haemodialysis patients
[7, 8]. However, due to lack of histological validation
of native T1 mapping in haemodialysis patients, it re-
mains possible that this increased native T1 signal
may be caused by increased myocardial water content,
either from myocardial oedema, chronic inflammation
or haemoglobin concentration rather than MF. We have
previously shown the reproducibility of circumferential
native T1 mapping to be excellent, and unrelated to
changes in markers of fluid status [42]. Confirming our
findings, a recent study, in which intra-dialytic CMR was
performed, showed that haemodialysis and ultrafiltration
had no acute effect on native T1 value [43]. Together,
these studies make it highly unlikely that myocardial
oedema from fluid overload contributes to elevated native
T1 in haemodialysis patients. It is possible that elevated
circumferential native T1 in haemodialysis is due to a
combination of high levels of DMF and low grade myocar-
dial inflammation or systematic differences within this
population such as anaemia.
Limitations
This is a single centre study with a relatively small
sample size, though larger than previous similar studies
[41, 44]. Whilst the technique of T11SD correlates with
FWHM for defining extent of MF, it did not correlate with
3SD, which is arguably a more accurate method of defin-
ing extent of MF in AS patients [17]. We do not have
histological validation of this technique, or histological
validation of native T1 mapping for the definition of MF
in patients with renal disease. The haemodialysis group
without discretely enhanced areas on native T1 map had
significantly lower systolic blood pressure, were younger
and were of a shorter dialysis vintage than haemodialysis
patients without areas of discretely increased signal on na-
tive T1 maps. Native T1 values are known to be higher in
patients with essential hypertension than controls [45]
and whilst we found no significant association between
blood pressure and native T1 amongst haemodialysis
patients we did observe a trend. Increased blood pres-
sure is likely to play a central role in the development
of DMF and replacement fibrosis in haemodialysis patients
as is time on dialysis and age, and these results should be
investigated further in larger studies. As expected, haemo-
globin was significantly lower in haemodialysis patients
compared to AS patients. Although values for haemoglo-
bin were in the target range for dialysis patients, (as
previously reported [30]), this may contribute to the higher
native T1 values we see in haemodialysis patients. We did
not, however, find any relationship between haemoglobin
and native T1 time in haemodialysis patients. We did not
observe any difference between global native T1 times or
T1 times in regions of greatest signal intensity between the
haemodialysis patients with and without coronary
artery disease. This might suggest processes related to
the effects of CKD and dialysis lead to the areas
Table 5 Inter and intra-observer variability for T11SD analysis in haemodialysis patients
Parameter Study 1 Study 2 ICC BIAS ± SD Difference BA Limits of Agreement
Inter-observer variability
T11SD 22.32 ± 7 22.6 ± 7.8 0.87 (p < 0.01) 0.5 ± 5.5 −10.2 – 11.21
Intra-observer variability
T11SD 22.32 ± 7 23.1 ± 8.1 0.96 (p < 0.01) −0.8 ± 3.1 −6.8 – 5.2
BA Bland-Altman, SD standard deviation
Graham-Brown et al. BMC Cardiovascular Disorders  (2018) 18:145 Page 10 of 12
native T1 and the global increases in native T1 that
we observed, but because there was no angiographic
component to this study we cannot be sure that
patients without a history of coronary artery disease
did not have occult, undiagnosed disease. In this
study LGE images were used as the reference values
for extent of MF. LGE is the gold-standard for the
identification and definition of replacement fibrosis, but
extracellular volume measurement (ECV) may be a better
non-invasive reference standard for quantification of
extent of MF, as ECV (like native T1 mapping) is a
continuous variable that allows quantification of ECV
expansion in LGE negative areas.
Conclusions
Visual identification of T1 maps was the most effective
technique at identifying areas of LGE in AS patients
which is considered our standard for MF evaluation. We
were unable to identify an absolute native T1 threshold
to define extent of MF. This work supports the position
of the Society for Cardiovascular Magnetic Resonance
and CMR Working Group of the European Society of
Cardiology that researchers must continue to phenotype
native T1 values across diseases, and define normal and
pathological ranges on individual scanners [46]. Histo-
logical studies are needed to assess the ability of native
T1 mapping and native T1 map signal thresholding tech-
niques to define extent of MF and replacement fibrosis
in patients with renal disease.
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